XINMARK is Xintela’s patented integrin technology platform that is being developed with the aim of commercialising innovative and improved treatments in two main areas: regenerative medicine and cancer. Within the cancer arena, Xintela’s research focuses on glioblastoma, an aggressive brain tumour, and this newsletter provides an update on our progress to date.
